Yahoo Finance

Operations: Sana Biotechnology, Inc. has not reported any revenue segments.

Market Cap: $654.18M

Sana Biotechnology, Inc., with a market cap of US$654.18 million, is pre-revenue and unprofitable, reflecting its developmental stage in the biotech sector. The company reported a net loss of US$266.76 million for 2024, an improvement from the previous year. Sana's short-term assets exceed its liabilities by a significant margin; however, it faces less than one year of cash runway based on current free cash flow trends. Despite high share price volatility and an inexperienced management team, recent promising clinical results from its UP421 cell therapy offer potential for future advancements without immunosuppression in type 1 diabetes treatment.

• Jump into the full analysis health report here for a deeper understanding of Sana Biotechnology.

• Review our growth performance report to gain insights into Sana Biotechnology's future.

SES AI

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SES AI Corporation focuses on developing and producing AI-enhanced Lithium Metal and Lithium-ion rechargeable battery technologies for various applications, including electric vehicles and robotics, with a market cap of approximately $160.38 million.

Operations: The company's revenue is derived from its Batteries / Battery Systems segment, amounting to $2.04 million.

Market Cap: $160.38M

SES AI Corporation, with a market cap of US$160.38 million, is navigating challenges typical for penny stocks. Despite its unprofitability and negative return on equity, SES has a cash runway exceeding three years and no debt, providing financial stability amid high share price volatility. Recent developments include a non-compliance notice from the NYSE due to low share prices, which SES aims to rectify within six months. The company projects significant revenue growth in 2025 driven by expanding partnerships and commercialization efforts in AI-enhanced battery technologies for electric vehicles and robotics applications.

• Click to explore a detailed breakdown of our findings in SES AI's financial health report.

• Evaluate SES AI's prospects by accessing our earnings growth report.

Summing It All Up

• Get an in-depth perspective on all 763 US Penny Stocks by using our screener here.

• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.

• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:MGRM NasdaqGS:SANA and NYSE:SES.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com